SAN DIEGO--(BUSINESS WIRE)--Dec. 9, 2005--Ligand Pharmaceuticals Incorporated (Pink Sheets:LGND) today announced the financial results for its first, second and third quarters of fiscal year 2005 and that the related Forms 10Q for such periods as reviewed by the company’s independent public accounting firm, BDO Seidman, LLP (“BDO”), have been filed with the Securities and Exchange Commission (SEC). “We are pleased to confirm the completion of our financial reporting normalization process and expect to submit shortly our application for relisting of our company stock on the NASDAQ National Market,” said David E. Robinson, Chairman, President and Chief Executive Officer of Ligand Pharmaceuticals.
